Bristol Myers Squibb Says Its Phase 2 LATTICE-UC Study Did N

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) on Thursday said its Phase 2 study of deucravacitinib dubbed LATTICE-UC in moderate to severe ulcerative colitis (UC) did not meet the primary

Related Keywords

Samit Hirawat , Bristol Myers Squibb , Myers Squibb , Bristol Myers , Bristol , Myers , Squibb , Ways , Hase , Lattice , Study , Feet , Primary , Objective ,